{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:15:41Z","timestamp":1790572541043,"version":"4.1.0"},"reference-count":50,"publisher":"Japan Atherosclerosis Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,3,1]]},"DOI":"10.5551\/jat.63587","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T22:09:43Z","timestamp":1654639783000},"page":"274-286","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia"],"prefix":"10.5551","volume":"30","author":[{"given":"Qidi","family":"Ying","sequence":"first","affiliation":[{"name":"Medical School, University of Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CNRS, INSERM, l\u2019institut du thorax"},{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, CNRS, SFR Sant\u00e9, INSERM UMS 016, CNRS UMS 3556"},{"name":"CRNH-Ouest Mass Spectrometry Core Facility"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick C","family":"Chan","sequence":"additional","affiliation":[{"name":"Medical School, University of Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute, St. Paul\u2019s Hospital, University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[{"name":"Medical School, University of Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Krempf","sequence":"additional","affiliation":[{"name":"Clinique Bret\u00e9ch\u00e9, Groupe Elsan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"Medical School, University of Western Australia"},{"name":"Lipid Disorders Clinic, Department of Cardiology and Internal Medicine, Royal Perth Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN: Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2020; 41: 2313-2330","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, Genest J, Ray KK, Vallejo-Vaz AJ: Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis. Circulation, 2020; 141: 1742-1759","DOI":"10.1161\/CIRCULATIONAHA.119.044795"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"5","unstructured":"5) Watts GF, Sullivan DR, Hare DL, Kostner KM, Horton AE, Bell DA, Brett T, Trent RJ, Poplawski NK, Martin AC, Srinivasan S, Justo RN, Chow CK, Pang J; FH Australasia Network Consensus Working Group: Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ, 2021; 30: 324-349"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Bor\u00e9n J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybj\u00e6rg-Hansen A; European Atherosclerosis Society Consensus Panel: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490","DOI":"10.1093\/eurheartj\/eht273"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chemello K, Garc\u00eda-Nafr\u00eda J, Gallo A, Mart\u00edn C, Lambert G, Blom D: Lipoprotein metabolism in familial hypercholesterolemia. J Lipid Res, 2021; 62: 100062","DOI":"10.1016\/j.jlr.2021.100062"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Chan DC, Watts GF: Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism, 2012; 61: 3-11","DOI":"10.1016\/j.metabol.2011.07.014"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokg\u00f6zo\u011flu LS, Tybjaerg-Hansen A, Stock JK, Catapano A: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Cohn JS, Lam CW, Sullivan DR, Hensley WJ: Plasma lipoprotein distribution of apolipoprotein(a) in the fed and fasted states. Atherosclerosis, 1991; 90: 59-66","DOI":"10.1016\/0021-9150(91)90244-W"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Marcoux C, Lussier-Cacan S, Davignon J, Cohn JS: Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects. Biochim Biophys Acta, 1997; 1346: 261-274","DOI":"10.1016\/S0005-2760(97)00049-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Alonso R, Andres E, Mata N, Fuentes-Jim\u00e9nez F, Badim\u00f3n L, L\u00f3pez-Miranda J, Padr\u00f3 T, Mu\u00f1iz O, D\u00edaz-D\u00edaz JL, Mauri M, Ordov\u00e1s JM, Mata P; SAFEHEART Investigators: Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol, 2014; 63: 1982-1989","DOI":"10.1016\/j.jacc.2014.01.063"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, Datta D, Capps N, Shoulders C, Qureshi N, Rees A, Main L, Cramb R, Viljoen A, Payne J, Soran H; HEART UK Medical, Scientific and Research Committee: HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis, 2019; 29: 62-70","DOI":"10.1016\/j.atherosclerosis.2019.10.011"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease: Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2022; 42: e48-e60","DOI":"10.1161\/ATV.0000000000000147"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Naito R, Daida H, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Koga N, Oikawa S, Yamashita S and Group FS: Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb, 2022; 29: 1188-1200","DOI":"10.5551\/jat.63019"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M and Ishihara M: Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions. J Atheroscler Thromb, 2021; 28: 555-561","DOI":"10.5551\/jat.56457"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M and Fukumoto Y: Serum Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. J Atheroscler Thromb, 2021; 28: 329-337","DOI":"10.5551\/jat.56390"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Schmidt K, Noureen A, Kronenberg F, Utermann G: Structure, function, and genetics of lipoprotein (a). J Lipid Res, 2016; 57: 1339-1359","DOI":"10.1194\/jlr.R067314"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J, Jr., Koschinsky ML, Morrisett JD: Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res, 2001; 42: 2058-2068","DOI":"10.1016\/S0022-2275(20)31535-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nestel PJ: Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr, 2000; 71: 228S-231S","DOI":"10.1093\/ajcn\/71.1.228S"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Goldenberg RM, Cheng AYY, Gilbert JD, Lonn EM, Pedersen SD, Verma S: The role of icosapent ethyl in cardiovascular risk reduction. Curr Opin Cardiol, 2021; 36: 661-671","DOI":"10.1097\/HCO.0000000000000873"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Weinberg RL, Brook RD, Rubenfire M, Eagle KA: Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC Focus Seminar. J Am Coll Cardiol, 2021; 77: 593-608","DOI":"10.1016\/j.jacc.2020.11.060"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chan DC, Pang J, Barrett PH, Sullivan DR, Burnett JR, van Bockxmeer FM, Watts GF: omega-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia. J Clin Endocrinol Metab, 2016; 101: 3732-3739","DOI":"10.1210\/jc.2016-2217"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Blanchard V, Gar\u00e7on D, Jaunet C, Chemello K, Billon-Crossouard S, Aguesse A, Garfa A, Famchon G, Torres A, Le May C, Pichelin M, Bigot-Corbel E, Lambert G, Cariou B, Hadjadj S, Krempf M, Bach-Ngohou K, Croyal M: A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. J Lipid Res, 2020; 61: 1128-1139","DOI":"10.1194\/jlr.D120000835"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Croyal M, Blanchard V, Ouguerram K, Ch\u00e9tiveaux M, Cabioch L, Moyon T, Billon-Crossouard S, Aguesse A, Bernardeau K, Le May C, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nob\u00e9court-Dupuy E: VLDL (very-low-density lipoprotein)-apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly. Arterioscler Thromb Vasc Biol, 2020; 40: 819-829","DOI":"10.1161\/ATVBAHA.119.313877"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Emancipator K: Low bias in assayed values of lipoprotein antigens--lipoprotein(a) and apolipoproteins A-I and B--in midday postprandial blood specimens compared with morning fasting specimens. Clin Chem, 1992; 38: 431-433","DOI":"10.1093\/clinchem\/38.3.431"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ishikawa T, Yamashita T, Mochizuki K, Suzuki K, Hashizume N, Nakamura H: Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake. J Atheroscler Thromb, 1995; 2 Suppl 1: S17-21","DOI":"10.5551\/jat1994.2.Supplement1_S17"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Souza DR, Maranh\u00e3o RC, Varella-Garcia M, Vilafanha D, Santos AB, Pileggi F, da Luz PL: Postprandial levels of lipoprotein(a) in subjects with or without coronary artery disease. Int J Cardiol, 1996; 53: 94-96","DOI":"10.1016\/0167-5273(95)02501-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hoppichler F, Kraft HG, Sandholzer C, Lechleitner M, Patsch JR, Utermann G: Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion. Atherosclerosis, 1996; 122: 127-134","DOI":"10.1016\/0021-9150(96)05803-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Pirro M, Lupattelli G, Siepi D, Palumbo B, Roscini AR, Marchesi S, Schillaci G, Mannarino E: Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women. Metabolism, 2001; 50: 330-334","DOI":"10.1053\/meta.2001.20202"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Igarashi M, Hirata A, Yamauchi T, Yamaguchi H, Tsuchiya H, Ohnuma H, Jimbu Y, Okuyama Y, Shirata T, Otsu N, Fukuyama H, Takahashi S, Tominaga M, Kato T: Clinical utility and approach to estimate postprandial hypertriglycemia by a newly designed oral fat-loading test. J Atheroscler Thromb, 2003; 10: 314-320","DOI":"10.5551\/jat.10.314"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH: Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol, 2015; 35: 2686-2693","DOI":"10.1161\/ATVBAHA.115.306136"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Bersot TP, Innerarity TL, Pitas RE, Rall SC, Jr., Weisgraber KH, Mahley RW: Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest, 1986; 77: 622-630","DOI":"10.1172\/JCI112345"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Devlin CM, Lee SJ, Kuriakose G, Spencer C, Becker L, Grosskopf I, Ko C, Huang LS, Koschinsky ML, Cooper AD, Tabas I: An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol, 2005; 25: 1704-1710","DOI":"10.1161\/01.ATV.0000170819.57945.03"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Edelstein C, Davidson NO, Scanu AM: Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids, 1994; 67-68: 135-143","DOI":"10.1016\/0009-3084(94)90132-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Youssef A, Clark JR, Marcovina SM, Boffa MB, Koschinsky ML: Apo(a) and apoB interact noncovalently within hepatocytes: Implications for regulation of lp(a) levels by modulation of apoB Secretion. Arterioscler Thromb Vasc Biol, 2022; 42: 289-304","DOI":"10.1161\/ATVBAHA.121.317335"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Rainwater DL, Lanford RE: Production of lipoprotein(a) by primary baboon hepatocytes. Biochim Biophys Acta, 1989; 1003: 30-35","DOI":"10.1016\/0005-2760(89)90094-5"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) D\u2019Erasmo L, Di Costanzo A, Gallo A, Bruckert E, Arca M: ApoCIII: A multifaceted protein in cardiometabolic disease. Metabolism, 2020; 113: 154395","DOI":"10.1016\/j.metabol.2020.154395"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Marais AD: Apolipoprotein E and atherosclerosis. Curr Atheroscler Rep, 2021; 23: 34","DOI":"10.1007\/s11883-021-00933-4"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PH: Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr, 2010; 91: 900-906","DOI":"10.3945\/ajcn.2009.28422"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ooi EM, Ng TW, Watts GF, Chan DC, Barrett PH: Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. J Lipid Res, 2012; 53: 2443-2449","DOI":"10.1194\/jlr.P029223"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S: Lipoprotein(a) mass levels increase significantly according to APOE genotype: An analysis of 431 239 patients. Arterioscler Thromb Vasc Biol, 2017; 37: 580-588","DOI":"10.1161\/ATVBAHA.116.308704"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF: Effect of \u03c9-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab, 2014; ; 99: E1427-1435","DOI":"10.1210\/jc.2013-4037"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J: Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol, 2010; 55: 2160-2167","DOI":"10.1016\/j.jacc.2009.10.080"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Tholstrup T, Samman S: Postprandial lipoprotein(a) is affected differently by specific individual dietary fatty acids in healthy young men. J Nutr, 2004; 134: 2550-2555","DOI":"10.1093\/jn\/134.10.2550"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM: Relationship between apo[a] isoforms and Lp[a] density in subjects with different apo[a] phenotype: a study before and after a fatty meal. J Lipid Res, 1991; 32: 679-683","DOI":"10.1016\/S0022-2275(20)42055-3"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, van Bockxmeer FM, Watts GF: Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol, 2015; 201: 633-638","DOI":"10.1016\/j.ijcard.2015.08.146"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Mori TA, Burke V, Puddey IB, Watts GF, O\u2019Neal DN, Best JD, Beilin LJ: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr, 2000; 71: 1085-1094","DOI":"10.1093\/ajcn\/71.5.1085"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Tsimikas S, Moriarty PM, Stroes ES: Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2\/4. J Am Coll Cardiol, 2021; 77: 1576-1589","DOI":"10.1016\/j.jacc.2021.01.051"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/3\/30_63587\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:49:33Z","timestamp":1715316573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/3\/30_63587\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63587","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"article-number":"63587"}}